Recruiting
Phase 1

Aleniglipron

Sponsor:

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Code:

NCT07872033

Conditions

Hepatic Impairment

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Aleniglipron

Study Details

Brief summary:

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.

Conditions

Hepatic Impairment

Study ID

NCT07872033

Start date

Oct 29, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening.
2. Female and male participants must follow protocol-specified contraception guidance as described in Section 5.4.2.1 and Section 5.4.2.2.
3. Is a continuous non-smoker or smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing. Participants must agree to maintain the same smoking status (i.e., smoker or non-smoker) from screening and until after the last PK sample collection.
4. BMI ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg at screening.
5. Understands the study procedures in the ICF and be willing and able to comply with the protocol and communicate effectively with study personnel.

Exclusion Criteria:

1. Is mentally or legally incapacitated or has significant emotional problems at the time of screening or expected during the conduct of the study.
2. History or presence of alcohol or drug abuse (including participants with symptoms of cannabis disorder) within the past 6 months prior to the dosing.
3. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
4. Female participant with a positive serum pregnancy test at screening or at check-in or who is lactating or breastfeeding.
5. Has positive drug results at screening or at check-in, unless the positive drug screen is due to prescription drug use that is approved by the PI or designee. Participants with a positive result for cannabinoids may be enrolled at the discretion of the PI or designee and the Sponsor.
6. Has taken medications intended to promote weight loss within 3 months or 5 half-lives, whichever is longer, prior to screening, including, but not limited to GLP-1 RAs.

Study Design

Enrollment

36 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Participants will receive aleniglipron administered orally Part 1

Aleniglipron administered orally.

experimental: Participants will receive aleniglipron administered orally Part 2

Aleniglipron administered orally.

Interventions

Aleniglipron

administered orally

Primary outcome measure

  • PK parameters including but not limited to AUC0-t [ Time Frame: Baseline to Day 5 (Part 1) ]
  • PK parameters including but not limited to AUC0-inf [ Time Frame: Baseline to Day 5 (Part 1) ]
  • PK parameters including but not limited to Cmax [ Time Frame: Baseline to Day 5 (Part 1) ]
  • PK parameters including but not limited to AUC0-t [ Time Frame: Baseline to Day 5 (Part 2) ]
  • PK parameters including but not limited to AUC0-inf [ Time Frame: Baseline to Day 5 (Part 2) ]
  • PK parameters including but not limited to Cmax [ Time Frame: Baseline to Day 5 (Part 2) ]

Central Contacts and Locations

Central contacts

Locations

Research Site

Recruiting

Orlando, Florida, United States, 32809

Contacts

Research Site

Recruiting

San Antonio, Texas, United States, 78215

Contacts

More Information

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Hepatic Impairment

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.